FDA National Priority Vouchers for Psychedelics

An April 2026 executive order from Donald Trump introduces major changes to how psychedelic drugs could be reviewed and accessed in the U.S. The policy creates two new pathways: a faster U.S. Food and Drug Administration review process using Commissioner’s National Priority Vouchers and expanded early access through the Right to Try Act. 

This first part focuses on CNPVs, which aim to shorten FDA review timelines from the standard 10 months to as little as one to two months. However, the program does not relax approval standards. Companies must still provide strong evidence on safety, effectiveness, and manufacturing quality. 

To qualify, psychedelic treatments must already have breakthrough therapy status and meet at least one of the FDA’s priority categories, such as addressing unmet medical needs or offering innovative therapies. Many psychedelic programs targeting conditions like depression or PTSD may fit these criteria, but eligibility depends on the specific drug, use, and readiness for submission. 

Unlike traditional priority review vouchers, CNPVs cannot be sold or transferred. Their value lies purely in speeding up time to market. Even so, early data suggests approval is not guaranteed, as less than half of awarded vouchers have led to approvals so far. 

The compressed timelines also create operational challenges. Companies must be fully prepared at submission, with completed clinical data, manufacturing plans, and regulatory documentation. They also need to manage additional hurdles linked to Schedule I substances, including DEA requirements and limited manufacturing capacity. 

Overall, the new pathway could significantly accelerate access to psychedelic therapies, especially for patients with serious mental health conditions. But success will depend on how prepared companies are to meet the FDA’s standards under much tighter timelines.